What is the Mayo Chronicity Score, how is it calculated on renal biopsy in ANCA-associated glomerulonephritis, and how does it inform prognosis and treatment decisions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mayo Chronicity Score in ANCA-Associated Glomerulonephritis

The Mayo Clinic Chronicity Score (MCCS) is a validated histopathologic grading system that quantifies chronic kidney damage on renal biopsy in ANCA-GN by scoring four components: glomerulosclerosis, interstitial fibrosis, tubular atrophy, and arteriosclerosis, with higher scores (0-12 scale) predicting worse renal outcomes and progression to kidney failure. 1

How the MCCS is Calculated

The MCCS evaluates four distinct chronic histologic features on kidney biopsy, each graded from 0-3:

  • Glomerulosclerosis: Percentage of globally sclerotic glomeruli
  • Interstitial fibrosis: Extent of fibrotic changes in the interstitium
  • Tubular atrophy: Degree of tubular loss and atrophy
  • Arteriosclerosis: Severity of arterial intimal sclerosis

Each component receives a score of 0-3 based on severity, yielding a total score ranging from 0-12. The MCCS is then categorized into four grades:

  • Minimal: MCCS 0-2 (31% of patients)
  • Mild: MCCS 3-4 (32% of patients)
  • Moderate: MCCS 5-7 (26% of patients)
  • Severe: MCCS 8-12 (11% of patients) 1

Prognostic Implications

Higher MCCS grades directly correlate with worse baseline kidney function and predict poor renal recovery, faster progression to kidney failure, and increased mortality. 1

Key Prognostic Findings:

  • Baseline kidney function: Mean eGFR decreases progressively across MCCS grades (48.3 vs 29.2 vs 23.7 vs 18.5 mL/min/1.73 m² for minimal through severe grades, respectively) 1

  • Renal recovery: Patients with lower MCCS grades recover kidney function significantly more frequently. This recovery is independent of whether cyclophosphamide or rituximab is used for induction therapy 1

  • Kidney failure prediction: MCCS ≥4 serves as a clinically useful cutoff for predicting progression to kidney failure. Each individual component (glomerulosclerosis, interstitial fibrosis, tubular atrophy, arteriosclerosis) independently predicts worse event-free survival 1

  • Time to events: Increasing MCCS grades associate with shorter time to kidney failure, combined kidney failure/death endpoint, and death alone 1

Clinical Application and Treatment Decisions

Despite unfavorable histologic findings, kidney recovery can occur even with advanced damage, and induction immunosuppressive treatment should not be withheld based solely on MCCS results. 2

Integration with Other Classification Systems:

The Mayo Clinic/Renal Pathology Society consensus guidelines recommend reporting ANCA-GN biopsies with multiple complementary elements 3:

  • Primary diagnosis: Specify MPO-ANCA or PR3-ANCA GN
  • Pattern of injury: Necrotizing and crescentic GN
  • Prognostic class: Use the Berden/EUVAS classification (focal, crescentic, mixed, or sclerotic based on predominant glomerular phenotype) 2
  • Additional features: Include MCCS components—percentage of globally sclerotic glomeruli, extent of interstitial fibrosis and tubular atrophy (IFTA), and severity of vascular changes 3

Comparison with Other Scoring Systems:

Recent validation studies demonstrate that the MCCS performs comparably to the ANCA Renal Risk Score (ARRS) for predicting kidney failure 4, 5. The newer improved ANCA Kidney Risk Score (AKRiS) shows enhanced discrimination (Harrell's C statistic 0.817) compared to MCCS alone (0.801), though the MCCS remains valuable as it focuses specifically on chronic damage 5.

Important Caveats

  • Persistent hematuria and proteinuria occur in 50% of patients during remission and do not necessarily indicate active disease. A stable or falling serum creatinine is more reliable for assessing remission 2

  • Histologic activity is unlikely without hematuria, but persisting proteinuria may reflect either ongoing activity or chronic parenchymal damage from prior inflammation 2

  • Repeat biopsy should be considered during follow-up if there is poor treatment response, as other causes of acute kidney injury unrelated to AAV may be present 2

  • Long-term prognostic performance of chronicity scores decreases over time. Incorporating post-therapy kidney function (peak eGFR attained after treatment) improves long-term prediction, as kidney relapses precipitate failure in 71% of cases progressing after the first year 5

References

1
Research

Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022

Related Questions

In a 26-year-old female with acute renal failure (serum creatinine 14 mg/dL), severe anemia, hyperphosphatemia, secondary hyperparathyroidism, and a positive perinuclear anti-neutrophil cytoplasmic antibody (p‑ANCA) level of 133 AU/mL after normal creatinine five months ago, what is the appropriate next management?
What is the recommended treatment for a patient with a cytoplasmic reticular antinuclear antibody (ANA) pattern, persistent proteinuria, and a steroid‑responsive proliferative glomerulonephritis?
What is the recommended treatment for sclerosing and focal crescentic pauci‑immune glomerulonephritis that is ANCA‑positive with high myeloperoxidase antibodies?
What is the recommended treatment for pauci‑immune perinuclear ANCA‑associated rapidly progressive glomerulonephritis?
What are the recommended indications, dosing regimen, and safety monitoring for clindamycin use in a pregnant patient during labor and delivery?
Which benzodiazepine has the longest duration of action when used as a sleep aid?
How should a painless, soft, mobile subcutaneous nodule beneath the clavicle (suspected lipoma) be evaluated and managed?
What is the recommended approach to manage sexual dysfunction in a patient taking temazepam (a benzodiazepine) for insomnia?
What are the recommended intrapartum dosing regimens for ampicillin, gentamicin, and clindamycin (including adjustments for β‑lactam allergy and Group B Streptococcus susceptibility) during labor and delivery?
In a patient with a swollen, red right eyelid from a stye, is treatment with a broad‑spectrum ophthalmic antibiotic ointment and a prednisone (Medrol) dose pack appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.